logo
Plus   Neg
Share
Email

ImaginAb, AstraZeneca, Pfizer, Takeda Join To Develop CD8 ImmunoPET Technology

ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, announced Monday that it has signed a multi-party collaboration deal with AstraZeneca Plc (AZN.L,AZN), Pfizer Inc. (PFE) and Takeda Pharmaceutical Co. Ltd. The agreement is focused on furthering the clinical development of ImaginAb's CD8 ImmunoPET technology.

Under the deal terms, the collaborators will help guide a current ImaginAb-sponsored clinical trial that aims to evaluate the utility and value of CD8 ImmunoPET in immuno-oncology drug development.

In return, the collaborators will gain early access to clinical and imaging data and collectively contribute to the post-trial data analysis.

The ImmunoPET technology uses ImaginAb's 'Minibody' platform, and targets and visualizes CD8+ T cells to provide highly-specific, quantitative assessment of the immunological status of each cancer lesion within a patient. This helps to tailor treatment quickly and specifically to the needs of that patient.

Ian Wilson, Chief Executive Officer of ImaginAb, said, " We believe that working with global leaders in immuno-oncology will help us further develop CD8 ImmunoPET as a pharmacodynamic marker for use in drug development and, in the future, as a diagnostic and predictive test for use in hospitals."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Panera Bread Co. is launching a new subscription program that will allow customers to drink unlimited coffee and tea. The new program of $8.99 per month launches Thursday and covers hot coffee, iced coffee and hot tea. With the introduction of the subscription, Panera becomes the first national restaurant company to offer unlimited hot drip coffee, iced coffee and hot tea for $8.99 per month. Best Buy Co. Inc. (BBY) Thursday reported a fourth-quarter profit that increased 1.4 percent from last year, while, J. C. Penney Co.'s (JCP) quarterly profit dropped 64 percent. However, the results of the companies topped analysts' estimates. Safavieh LLC recalled about 760 units of Aura and Silas 3-Drawer Chests for possible serious tip-over and entrapment hazards that can result in death or injuries to children, the U.S. Consumer Product Safety Commission said in a statement. The company said the chests are unstable if they are not anchored to the wall.
Follow RTT
>